Keyphrases
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
100%
National Cohort Study
75%
Myocardial Infarction
62%
Atrial Fibrillation
58%
Cardiovascular Risk
48%
Drug Use
35%
Confidence Interval
32%
Hazard Ratio
23%
Drug Treatment
19%
Levothyroxine
18%
Antithrombotic Therapy
16%
Bleeding Risk
15%
Heart Failure
15%
Myocardial Infarction Patients
14%
Cardiovascular Safety
14%
Clopidogrel
13%
Oral Anticoagulation
12%
Prior Myocardial Infarction
12%
Denmark
12%
Subclinical Hypothyroidism
12%
Hypertrophic Cardiomyopathy
12%
New-onset Atrial Fibrillation
12%
Gastrointestinal Bleeding
12%
Catheter Ablation
12%
Incidence Rate
11%
Comorbidity
11%
Pharmacotherapy
10%
All-cause Mortality
10%
Post-myocardial Infarction
10%
Cardiovascular Mortality
10%
Nationwide Registry
10%
Diclofenac
9%
Nationwide Registers
9%
Treatment Duration
9%
Risk of Death
8%
Thromboembolism
8%
Temporal Trends
8%
Diabetes
8%
Coronary Intervention
8%
Drug Therapy
8%
Cardiovascular Events
7%
Retrospective Cohort Study
7%
Naproxen
7%
Odds Ratio
7%
Non-aspirin Non-steroidal Anti-inflammatory Drugs
7%
Bleeding Events
7%
Recurrent Myocardial Infarction
7%
Thyroid Disease
7%
Thyroid Function
7%
Statins
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non-Steroidal Anti-Inflammatory Drug
90%
Heart Infarction
75%
Cohort Study
69%
Atrial Fibrillation
41%
Pharmacotherapy
36%
Cardiovascular Risk
35%
Heart Failure
21%
Acetylsalicylic Acid
19%
Anticoagulant Agent
19%
Levothyroxine
18%
Antithrombotic Therapy
13%
Clopidogrel
13%
Gastrointestinal Hemorrhage
12%
Subclinical Hypothyroidism
12%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Diclofenac
9%
Comorbidity
8%
Ibuprofen
8%
Bleeding
7%
Thrombosis
7%
Ischemic Heart Disease
7%
Cardiovascular Disease
7%
Naproxen
7%
All Cause Mortality
7%
Thromboembolism
6%
Diabetes Mellitus
6%
Statin (Protein)
6%
Brain Ischemia
6%
Proprotein Convertase 9
6%
Osteoarthritis
6%
Out of Hospital Cardiac Arrest
6%
Heart Arrhythmia
6%
New-Onset Atrial Fibrillation
6%
Adverse Event
6%
Disease Severity
6%
Acute Heart Infarction
6%
Combination Therapy
6%
Antiplatelet
6%
Cerebrovascular Disease
6%
Hyperthyroidism
6%
Venous Thromboembolism
6%
Normal Human
6%
Warfarin
6%
Dabigatran
6%
Antivitamin K
6%
Coronary Artery Disease
6%
Hypertrophic Cardiomyopathy
6%
Cardiovascular Agent
6%
Proton Pump Inhibitor
6%
Heart Disease
6%
Medicine and Dentistry
Nonsteroid Antiinflammatory Agent
48%
Cohort Analysis
42%
Atrial Fibrillation
38%
Apoplexy
22%
Drug Use
21%
Myocardial Infarction
19%
Antithrombotic
14%
Cardiovascular Risk
14%
Drug Therapy
13%
Gastrointestinal Bleeding
12%
New-Onset Atrial Fibrillation
12%
Hypertrophic Cardiomyopathy
12%
Heart Failure
9%
Diabetes
9%
Cardiovascular System
8%
Acetylsalicylic Acid
7%
Antithrombotic Therapy
7%
Anticoagulation
6%
Diabetes Mellitus
6%
Hazard Ratio
6%
Cardiovascular Disease
6%
Risk Stratification
6%
Proton-Pump Inhibitor
6%
Rheumatoid Arthritis
6%
Retrospective Cohort Study
6%
Thyroid Function
6%
Thyroid Disease
6%
Hyperthyroidism
6%
Vitamin K Antagonist
6%
Proprotein Convertase 9
6%
Catheter Ablation
6%
Cardiovascular Effect
6%
Thromboembolism
6%